Correlation Between MaxCyte and CeriBell,
Can any of the company-specific risk be diversified away by investing in both MaxCyte and CeriBell, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MaxCyte and CeriBell, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between MaxCyte and CeriBell,, you can compare the effects of market volatilities on MaxCyte and CeriBell, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MaxCyte with a short position of CeriBell,. Check out your portfolio center. Please also check ongoing floating volatility patterns of MaxCyte and CeriBell,.
Diversification Opportunities for MaxCyte and CeriBell,
Excellent diversification
The 3 months correlation between MaxCyte and CeriBell, is -0.62. Overlapping area represents the amount of risk that can be diversified away by holding MaxCyte and CeriBell, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CeriBell, and MaxCyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MaxCyte are associated (or correlated) with CeriBell,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CeriBell, has no effect on the direction of MaxCyte i.e., MaxCyte and CeriBell, go up and down completely randomly.
Pair Corralation between MaxCyte and CeriBell,
Given the investment horizon of 90 days MaxCyte is expected to generate 1.1 times more return on investment than CeriBell,. However, MaxCyte is 1.1 times more volatile than CeriBell,. It trades about 0.0 of its potential returns per unit of risk. CeriBell, is currently generating about -0.08 per unit of risk. If you would invest 355.00 in MaxCyte on November 29, 2024 and sell it today you would lose (12.00) from holding MaxCyte or give up 3.38% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
MaxCyte vs. CeriBell,
Performance |
Timeline |
MaxCyte |
CeriBell, |
MaxCyte and CeriBell, Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with MaxCyte and CeriBell,
The main advantage of trading using opposite MaxCyte and CeriBell, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MaxCyte position performs unexpectedly, CeriBell, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CeriBell, will offset losses from the drop in CeriBell,'s long position.MaxCyte vs. Sight Sciences | MaxCyte vs. CVRx Inc | MaxCyte vs. Neuropace | MaxCyte vs. Rapid Micro Biosystems |
CeriBell, vs. Highwoods Properties | CeriBell, vs. Franklin Street Properties | CeriBell, vs. Genfit | CeriBell, vs. JBG SMITH Properties |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Complementary Tools
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Stocks Directory Find actively traded stocks across global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
CEOs Directory Screen CEOs from public companies around the world |